BRPI0814548A2 - Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila - Google Patents

Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila

Info

Publication number
BRPI0814548A2
BRPI0814548A2 BRPI0814548-2A2A BRPI0814548A BRPI0814548A2 BR PI0814548 A2 BRPI0814548 A2 BR PI0814548A2 BR PI0814548 A BRPI0814548 A BR PI0814548A BR PI0814548 A2 BRPI0814548 A2 BR PI0814548A2
Authority
BR
Brazil
Prior art keywords
amino
dimethylphylen
benzonitril
cyanoethenyl
pyrimidinyl
Prior art date
Application number
BRPI0814548-2A2A
Other languages
English (en)
Inventor
Sigrid Carl Maria Stokbroekx
Carina Leys
Elisabeth Maria Helene Egide Ghislaine Theunissen
Lieven Elvire Colette Baert
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38706528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814548(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0814548A2 publication Critical patent/BRPI0814548A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0814548-2A2A 2007-07-12 2008-07-11 Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila BRPI0814548A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07112392 2007-07-12
PCT/EP2008/059054 WO2009007441A2 (en) 2007-07-12 2008-07-11 Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile

Publications (1)

Publication Number Publication Date
BRPI0814548A2 true BRPI0814548A2 (pt) 2015-01-06

Family

ID=38706528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814548-2A2A BRPI0814548A2 (pt) 2007-07-12 2008-07-11 Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila

Country Status (15)

Country Link
US (1) US8426434B2 (pt)
EP (1) EP2175857B1 (pt)
JP (1) JP5701057B2 (pt)
CN (1) CN101743006B (pt)
AU (1) AU2008274185B2 (pt)
BR (1) BRPI0814548A2 (pt)
CA (1) CA2693044C (pt)
DK (1) DK2175857T3 (pt)
ES (1) ES2437331T3 (pt)
HK (1) HK1144669A1 (pt)
HR (1) HRP20131128T1 (pt)
IL (1) IL202363A (pt)
RU (1) RU2498979C2 (pt)
SI (1) SI2175857T1 (pt)
WO (1) WO2009007441A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
PL2480220T3 (pl) * 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
DK3494972T3 (da) * 2010-01-27 2024-01-29 Viiv Healthcare Co Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
BR112013026363B1 (pt) * 2011-04-15 2021-10-13 Janssen Pharmaceutica Nv Nanossuspensões compreendendo 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil] amino] benzonitrila, seu processo de preparação e composição farmacêutica para administração por injeção intramuscular ou subcutânea
EP2628732A1 (en) * 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
WO2013087794A1 (en) * 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2604593A1 (en) * 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2014093941A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Pharmaceutical compositions
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN109890808B (zh) 2016-08-19 2020-08-07 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
JP2006508145A (ja) 2002-11-15 2006-03-09 テイボテク・フアーマシユーチカルズ・リミテツド 抗感染化合物としての置換インドールピリジニウム
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法

Also Published As

Publication number Publication date
CA2693044C (en) 2017-03-14
US8426434B2 (en) 2013-04-23
RU2010104848A (ru) 2011-08-20
ES2437331T3 (es) 2014-01-10
EP2175857A2 (en) 2010-04-21
IL202363A (en) 2016-04-21
AU2008274185B2 (en) 2014-07-03
US20100189796A1 (en) 2010-07-29
HK1144669A1 (pt) 2011-03-04
SI2175857T1 (sl) 2014-01-31
WO2009007441A2 (en) 2009-01-15
WO2009007441A3 (en) 2009-04-30
CN101743006B (zh) 2013-09-11
AU2008274185A1 (en) 2009-01-15
DK2175857T3 (da) 2013-12-02
CA2693044A1 (en) 2009-01-15
CN101743006A (zh) 2010-06-16
RU2498979C2 (ru) 2013-11-20
HRP20131128T1 (hr) 2013-12-20
IL202363A0 (en) 2010-06-30
JP5701057B2 (ja) 2015-04-15
EP2175857B1 (en) 2013-09-11
JP2010533148A (ja) 2010-10-21

Similar Documents

Publication Publication Date Title
BRPI0814548A2 (pt) Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2 pirimidinil]amino]benzonitrila
LTC3106463I2 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
HK1146042A1 (en) Pyrimidine derivatives as protein kinase inhibitors
CO6811863A2 (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES2465673T9 (es) Derivados de pirimidina
CY2016050I1 (el) Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
ZA201108779B (en) Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ZA201003875B (en) Novel pyrimidine derivatives
IL218543A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ZA200808364B (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
IL226474A0 (en) Crystal forms of 5-chloro-n2-@@-isopropoxy-@-methyl-4-piperidine-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]pyrimidine-4,2-diamine
CU20090141A7 (es) Compuestos 2-amino pirimidina
BRPI0916679A2 (pt) 5-alquinil-pirimidinas
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
BRPI1009398A2 (pt) compostos de pirimidina fundida substituída
BRPI1013493A2 (pt) composto de pirimidina
HK1215434A1 (zh) 取代的嘧啶衍生物

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]